Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase Activities

Selective Action of Human Paraoxonase Allozymes Q and R

From the Lipid Research Laboratory, Technion Faculty of Medicine, the Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa, Israel (M.A., M.R.); and the Department of Vascular and Cardiac Diseases, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, (C.B., R.N.), and the Departments of Pharmacology and Anesthesiology, The University of Michigan Medical School (S.B., R.S., J.E., C.H., C.D., B.L.D.), Ann Arbor, Mich.

Correspondence to Prof Michael Aviram, Lipid Research Laboratory, Rambam Medical Center, Bat-Galim, Haifa, Israel 31096. E-mail aviram{at}tx.technion.ac.il

Abstract—Human serum paraoxonase (PON 1) exists in 2 major polymorphic forms (Q and R), which differ in the amino acid at position 191 (glutamine and arginine, respectively). These PON allozymes hydrolyze organophosphates and aromatic esters, and both also protect LDL from copper ion–induced oxidation. We have compared purified serum PONs of both forms and evaluated their effects on LDL oxidation, in respect to their arylesterase/paraoxonase activities. Copper ion–induced LDL oxidation, measured by the production of peroxides and aldehydes after 4 hours of incubation, were reduced up to 61% and 58%, respectively, by PON Q, but only up to 46% and 38%, respectively, by an equivalent concentration of PON R. These phenomena were PON-concentration dependent. Recombinant PON Q and PON R demonstrated similar patterns to that shown for the purified serum allozymes. PON Q and PON R differences in protection of LDL against oxidation were further evaluated in the presence of glutathione peroxidase (GPx). GPx (0.1 U/mL) alone reduced copper ion–induced LDL oxidation by 20% after 4 hours of incubation. The addition of PON R to the above system resulted in an additive inhibitory effect on LDL oxidation, whereas PON Q had no such additive effect. The 2 PON allozymes also differed by their ability to inhibit initiation, as well as propagation, of LDL oxidation. PON Q was more efficient in blocking LDL oxidation if added when oxidation was initiated, whereas PON R was more potent when added 1 hour after the initiation of LDL oxidation. These data suggest that the 2 allozymes act on different substrates. Both PON allozymes were also able to reduce the oxidation of phospholipids and cholesteryl ester. PON Q arylesterase activity was reduced after 4 hours of LDL oxidation by only 28%, whereas the arylesterase activity of PON R was reduced by up to 55%. Inactivation of the calcium-dependent PON arylesterase activity by using the metal chelator EDTA, or by calcium ion removal on a Chelex column, did not alter PON's ability to inhibit LDL oxidation. However, blockage of the PON free sulfhydryl group at position 283 with p-hydroxymercuribenzoate inhibited both its arylesterase activity and its protection of LDL from oxidation. Recombinant PON mutants in which the PON free sulfhydryl group was replaced by either alanine or serine were no longer able to protect against LDL oxidation, even though they retained paraoxonase and arylesterase activities. Overall, these studies demonstrate that PON's arylesterase/paraoxonase activities and the protection against LDL oxidation do not involve the active site on the enzyme in exactly the same way, and PON's ability to protect LDL from oxidation requires the cysteine residue at position 283.

Key Words: paraoxonase • arylesterase • LDL • lipid peroxidation • sulfhydryl group

This article has been cited by other articles:

				J. J. Regieli, J. W. Jukema, P. A. Doevendans, A. H. Zwinderman, J. J. Kastelein, D. E. Grobbee, and Y. van der Graaf Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1238 - 1245. [Abstract] [Full Text] [PDF]

				A. ARPACI, U. GORMUS, B. DALAN, S. BERKMAN, and T. ISBIR Investigation of PON1 192 and PON1 55 Polymorphisms in Ovarian Cancer Patients in Turkish Population In Vivo, May 1, 2009; 23(3): 421 - 424. [Abstract] [Full Text] [PDF]

				Y.-J. Park, S.-J. Yoon, and H.-B. Lee A Novel Thermostable Arylesterase from the Archaeon Sulfolobus solfataricus P1: Purification, Characterization, and Expression J. Bacteriol., December 15, 2008; 190(24): 8086 - 8095. [Abstract] [Full Text] [PDF]

				Y.-C. Liao, H.-F. Lin, T. Rundek, R. Cheng, Y.-C. Guo, R. L. Sacco, and S.-H. H. Juo Segment-Specific Genetic Effects on Carotid Intima-Media Thickness: The Northern Manhattan Study Stroke, December 1, 2008; 39(12): 3159 - 3165. [Abstract] [Full Text] [PDF]

				L. Gaidukov and D. S. Tawfik The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity J. Lipid Res., July 1, 2007; 48(7): 1637 - 1646. [Abstract] [Full Text] [PDF]

				L. Gaidukov, M. Rosenblat, M. Aviram, and D. S. Tawfik The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux J. Lipid Res., November 1, 2006; 47(11): 2492 - 2502. [Abstract] [Full Text] [PDF]

				M. Graner, R. W. James, J. Kahri, M. S. Nieminen, M. Syvanne, and M.-R. Taskinen Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2429 - 2435. [Abstract] [Full Text] [PDF]

				F. Marchegiani, M. Marra, L. Spazzafumo, R. W. James, M. Boemi, F. Olivieri, M. Cardelli, L. Cavallone, A. R. Bonfigli, and C. Franceschi Paraoxonase activity and genotype predispose to successful aging. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 541 - 546. [Abstract] [Full Text] [PDF]

				C. S. Carlson, P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease J. Lipid Res., May 1, 2006; 47(5): 1014 - 1024. [Abstract] [Full Text] [PDF]

				M. Rosenblat, L. Gaidukov, O. Khersonsky, J. Vaya, R. Oren, D. S. Tawfik, and M. Aviram The Catalytic Histidine Dyad of High Density Lipoprotein-associated Serum Paraoxonase-1 (PON1) Is Essential for PON1-mediated Inhibition of Low Density Lipoprotein Oxidation and Stimulation of Macrophage Cholesterol Efflux J. Biol. Chem., March 17, 2006; 281(11): 7657 - 7665. [Abstract] [Full Text] [PDF]

				K. Ranade, T. G. Kirchgessner, O. A. Iakoubova, J. J. Devlin, T. DelMonte, P. Vishnupad, L. Hui, Z. Tsuchihashi, F. M. Sacks, M. S. Sabatine, et al. Evaluation of the Paraoxonases as Candidate Genes for Stroke: Gln192Arg Polymorphism in the Paraoxonase 1 Gene Is Associated With Increased Risk of Stroke Stroke, November 1, 2005; 36(11): 2346 - 2350. [Abstract] [Full Text] [PDF]

				L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]

				F. Rodriguez-Esparragon, J. C. Rodriguez-Perez, Y. Hernandez-Trujillo, A. Macias-Reyes, A. Medina, A. Caballero, and C. M. Ferrario Allelic Variants of the Human Scavenger Receptor Class B Type 1 and Paraoxonase 1 on Coronary Heart Disease: Genotype-Phenotype Correlations Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 854 - 860. [Abstract] [Full Text] [PDF]

				J. F. Teiber, D. I. Draganov, and B. N. La Du Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH J. Lipid Res., December 1, 2004; 45(12): 2260 - 2268. [Abstract] [Full Text] [PDF]

				S. D. Nguyen and D.-E. Sok Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids J. Lipid Res., December 1, 2004; 45(12): 2211 - 2220. [Abstract] [Full Text] [PDF]

				W. H. F. Sutherland, S. A. de Jong, and R. J. Walker Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study Nephrol. Dial. Transplant., January 1, 2004; 19(1): 75 - 82. [Abstract] [Full Text] [PDF]

				S. Kopprasch, J. Pietzsch, E. Kuhlisch, and J. Graessler Lack of Association between Serum Paraoxonase 1 Activities and Increased Oxidized Low-Density Lipoprotein Levels in Impaired Glucose Tolerance and Newly Diagnosed Diabetes Mellitus J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1711 - 1716. [Abstract] [Full Text] [PDF]

				V. G. Cabana, C. A. Reardon, N. Feng, S. Neath, J. Lukens, and G. S. Getz Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response J. Lipid Res., April 1, 2003; 44(4): 780 - 792. [Abstract] [Full Text] [PDF]

				O. Rozenberg, D. M. Shih, and M. Aviram Human Serum Paraoxonase 1 Decreases Macrophage Cholesterol Biosynthesis: Possible Role for Its Phospholipase-A2-Like Activity and Lysophosphatidylcholine Formation Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 461 - 467. [Abstract] [Full Text] [PDF]

				G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre Platelet-activating Factor Acetylhydrolase, and Not Paraoxonase-1, Is the Oxidized Phospholipid Hydrolase of High Density Lipoprotein Particles J. Biol. Chem., January 31, 2003; 278(6): 3937 - 3947. [Abstract] [Full Text] [PDF]

				G. Zuliani, A. Cherubini, S. Volpato, E. Palmieri, P. Mecocci, P. De Rango, P. Cao, F. Costantini, A. Mezzetti, F. Mascoli, et al. Genetic Factors Associated With the Absence of Atherosclerosis in Octogenarians J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2002; 57(9): M611 - 615. [Abstract] [Full Text] [PDF]

				M. Tomas, R. Elosua, M. Senti, L. Molina, J. Vila, R. Anglada, M. Fito, M. I. Covas, and J. Marrugat Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity J. Lipid Res., May 1, 2002; 43(5): 713 - 720. [Abstract] [Full Text] [PDF]

				D. S. Ng, G. F. Maguire, J. Wylie, A. Ravandi, W. Xuan, Z. Ahmed, M. Eskandarian, A. Kuksis, and P. W. Connelly Oxidative Stress Is Markedly Elevated in Lecithin:Cholesterol Acyltransferase-deficient Mice and Is Paradoxically Reversed in the Apolipoprotein E Knockout Background in Association with a Reduction in Atherosclerosis J. Biol. Chem., March 29, 2002; 277(14): 11715 - 11720. [Abstract] [Full Text] [PDF]

				T. M. Forte, G. Subbanagounder, J. A. Berliner, P. J. Blanche, A. O. Clermont, Z. Jia, M. N. Oda, R. M. Krauss, and J. K. Bielicki Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice J. Lipid Res., March 1, 2002; 43(3): 477 - 485. [Abstract] [Full Text] [PDF]

				M. Kaplan, T. Hayek, A. Raz, R. Coleman, L. Dornfeld, J. Vaya, and M. Aviram Pomegranate Juice Supplementation to Atherosclerotic Mice Reduces Macrophage Lipid Peroxidation, Cellular Cholesterol Accumulation and Development of Atherosclerosis J. Nutr., August 1, 2001; 131(8): 2082 - 2089. [Abstract] [Full Text] [PDF]

				R. J. Brushia, T. M. Forte, M. N. Oda, B. N. La Du, and J. K. Bielicki Baculovirus-mediated expression and purification of human serum paraoxonase 1A J. Lipid Res., June 1, 2001; 42(6): 951 - 958. [Abstract] [Full Text]

				M. Navab, J. A. Berliner, G. Subbanagounder, S. Hama, A. J. Lusis, L. W. Castellani, S. Reddy, D. Shih, W. Shi, A. D. Watson, et al. HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids Arterioscler Thromb Vasc Biol, April 1, 2001; 21(4): 481 - 488. [Abstract] [Full Text] [PDF]

				S. T. Reddy, D. J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D. M. Shih, A. J. Lusis, M. Navab, and A. M. Fogelman Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids Arterioscler Thromb Vasc Biol, April 1, 2001; 21(4): 542 - 547. [Abstract] [Full Text] [PDF]

				S. Billecke, D. Draganov, R. Counsell, P. Stetson, C. Watson, C. Hsu, and B. N. L. Du Human Serum Paraoxonase (pon1) Isozymes Q and R Hydrolyze Lactones and Cyclic Carbonate Esters Drug Metab. Dispos., November 1, 2000; 28(11): 1335 - 1342. [Abstract] [Full Text]

				M. Navab, S. Y. Hama, C. J. Cooke, G. M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K. F. Faull, S. T. Reddy, N. E. Miller, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1 J. Lipid Res., September 1, 2000; 41(9): 1481 - 1494. [Abstract] [Full Text]

				T. Kujiraoka, T. Oka, M. Ishihara, T. Egashira, T. Fujioka, E. Saito, S. Saito, N. E. Miller, and H. Hattori A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration J. Lipid Res., August 1, 2000; 41(8): 1358 - 1363. [Abstract] [Full Text]

				M. Aviram, E. Hardak, J. Vaya, S. Mahmood, S. Milo, A. Hoffman, S. Billicke, D. Draganov, and M. Rosenblat Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions : PON1 Esterase and Peroxidase-Like Activities Circulation, May 30, 2000; 101(21): 2510 - 2517. [Abstract] [Full Text] [PDF]

				C. Bauters, C. Amant, A. Boulier, P. Cabrol, E. McFadden, P. Duriez, M. E. Bertrand, and P. Amouyel Paraoxonase Polymorphism (Gln192Arg) as a Determinant of the Response of Human Coronary Arteries to Serotonin Circulation, February 22, 2000; 101(7): 740 - 743. [Abstract] [Full Text] [PDF]

				C Aubo, M Senti, J Marrugat, M Tomas, J Vila, J Sala, and R Masia Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus Eur. Heart J., January 1, 2000; 21(1): 33 - 38. [Abstract] [PDF]

				R. C. Sorenson, C. L. Bisgaier, M. Aviram, C. Hsu, S. Billecke, and B. N. La Du Human Serum Paraoxonase/Arylesterase's Retained Hydrophobic N-Terminal Leader Sequence Associates With HDLs by Binding Phospholipids : Apolipoprotein A-I Stabilizes Activity Arterioscler Thromb Vasc Biol, September 1, 1999; 19(9): 2214 - 2225. [Abstract] [Full Text] [PDF]

				D. I. Draganov, P. L. Stetson, C. E. Watson, S. S. Billecke, and B. N. La Du Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation J. Biol. Chem., October 20, 2000; 275(43): 33435 - 33442. [Abstract] [Full Text] [PDF]

				Z. Ahmed, A. Ravandi, G. F. Maguire, A. Emili, D. Draganov, B. N. L. Du, A. Kuksis, and P. W. Connelly Apolipoprotein A-I Promotes the Formation of Phosphatidylcholine Core Aldehydes That Are Hydrolyzed by Paraoxonase (PON-1) during High Density Lipoprotein Oxidation with a Peroxynitrite Donor J. Biol. Chem., June 29, 2001; 276(27): 24473 - 24481. [Abstract] [Full Text] [PDF]

				C. J. Ng, D. J. Wadleigh, A. Gangopadhyay, S. Hama, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein J. Biol. Chem., November 21, 2001; 276(48): 44444 - 44449. [Abstract] [Full Text] [PDF]